Hey, as a follow up, seems I was wrong. I just came across a monoclonal antibody that is delivered orally via Phloral™ and Soteria™ technologies. Haven't done a deep dive as to how these delivery mechanisms work though. The target for this drug is the colon, so I'm guessing this delivery system inhibits digestion until absorption in the colon? I don't think this would apply to the majority of Leronlimab targets, maybe if we get into the crohns and colitis space though.